Skip to main content
. 2017 Jun 5;4(4):e360. doi: 10.1212/NXI.0000000000000360

Figure 2. Cladribine preferentially depletes B lymphocytes compared with a modest depletion of T cells.

Figure 2

The results represent the mean percentage ± SEM of blood lymphocytes compared with baseline following treatment with either placebo (circle; n = 56–79) or total doses of either 3.5 mg/kg (diamond; n = 62–82) or 5.25/kg (hexagon; n = 66–81) cladribine (CLAD) administered in monthly courses (inverse triangle) at 0, 5 and 48 and 52 weeks (3.5 mg per dose) and additionally at 9 and 13 weeks (5.25 mg per dose). Results show the numbers of (A) CD3+ T cells, (B) CD19+ B cells, (C) CD4+ T cells (D) CD8+ T cells, and (E) CD4+-naive and (F) CD4+ memory T cells.